top of page
Development Pipeline
ACX02
Applied Cognition’s lead candidate, ACX02 — a fixed-dose small molecule combination with a pending new molecular entity (NME) patent — is designed to enhance the therapeutic benefits of natural sleep while simultaneously engaging the three critical brain physiologies that drive glymphatic function.
ACX04-18
Through its platform, Applied Cognition has uncovered a link between neurovascular function and astrocyte-mediated neuropil resistance, revealing a novel druggable target in humans. The company is actively probing this CNS target using specialized tool compounds, with the goal of discovering new drugs for development and licensing opportunities.
Pharma Program
Applied Cognition is actively advancing early licensing discussions for its platform, which is designed to predict the translational success of new therapeutic modalities targeting glymphatic clearance of toxic proteins in Alzheimer’s disease and related dementias.
bottom of page